Kornimate/medical-research-clean huggingface dataset:
concurrent endostar, paclitaxel/carboplatin and radiotherapy for locally advanced non-small cell lung (rt0902)

Conditions: Non-small Cell Lung Cancer

Summary: concomitant chemoradiotherapy is the standard treatment of locally advanced, non-resectable, non-small cell lung cancer (nsclc). however, the optimal chemotherapy regimen is still controversial. the purpose of this study was to evaluate the efficacy and toxicity of a concomitant treatment using endostar (recombinant human endostatin), paclitaxel/carboplatin and radiotherapy for la-nsclc, and also assess its impact on patient quality of life (qol) and progression-free survival (pfs).

patients with non-resectable non-small cell lung cancer will receive thoracic radiation therapy 60-66 gy over 30-33 fractions and concurrent with endostar 7.5 mg/m2 over 3 hours d1-14, paclitaxel 50 mg/m2 weekly over 1 hour, carboplatin auc = 2 mg/ml/min over 30 min weekly. followed by endostar 7.5 mg/m2 d1-14,paclitaxel 175 mg/m2 d1 and carboplatin auc = 5 mg/ml/min d1 every 3 weeks for 2 cycles as consolidation treatment.

Eligibility criteria:
inclusion criteria: * histologically proven non-small cell lung cancer (squamous cell carcinoma, adenocarcinoma, large cell carcinoma and etc) * presence of measurable disease by recist * stage iiia or iiib, non-resectable * ecog performance status 0-1 * no prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy .patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital. exclusion criteria: * carcinoid tumor, small cell carcinoma of lung * patients with any distant metastasis * history of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix * any other morbidity or situation with contraindication for radiotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment) * pregnant or lactating women, women who has not taken test of pregnancy (within 7 days before the first administration) and pregnant women * women and men of childbearing potential who have no willing of employing adequate contraception tumor egfr wild

Keywords: non-small cell lung cancer locally advanced radiotherapy concomitant chemotherapy endostar
treatment of pulmonary hypertension associated copd with inhaled treprostinil-1

Conditions: Pulmonary Hypertension; COPD

Summary: an open label, pilot study testing the safety and efficacy of inhaled treprostinil (tyvaso®) in the treatment of pulmonary hypertension (ph) associated with chronic obstructive pulmonary disease (copd)

this is a pilot study of 10 patients that have copd-ph. primary outcome measure is to see if this drug is safe for this patient population and the secondary measure is to see if the drug improves patient functional capacity.

Eligibility criteria:
inclusion criteria: must have: * be between the ages of 30 and 80 * have a clinical diagnosis of gold stage 2 to 4 copd * have a diagnosis of pulmonary hypertension established by a historic right heart catheterization * a minimum weight of 45 kg * minimum systolic blood pressure of \>90 mmhg * be able to perform a six minute walk test * be able to maintain a oxygen saturation \>88% at rest (with or without oxygen) * be treated with background therapy for copd for a minimum of 1 month prior to consideration of enrollment. * be competent to understand the information given in the institutional review board (irb) or independent ethics committee (iec) approved informed consent form and must sign the form prior to the initiation of any study procedure. exclusion criteria. cannot have or be: * the presence of pulmonary venous hypertension defined by a historical right heart catheterization * gold stage i copd * documented left ventricular dysfunction as measured by echocardiography * pregnant or breastfeeding * recipient of a lung transplant * received chronic prostanoid therapy for pulmonary hypertension within 4 weeks prior to the screening appointment * a requirement of greater than 9 l/min of o2 to maintain oxygen saturations greater than 88% at rest * no other serious medical conditions

Keywords: copd ph copd associated pulmonary hypertension copd and pulmonary hypertension disease
citalopram for sx/util in acute coronary syndrome patients

Conditions: Acute Coronary Syndrome

Summary: symptoms (chest pain, shortness of breath, dizziness, etc.) and treatment usage (doctor or emergency room visits, testing, hospital days, etc.) in patients with acute coronary syndromes are known to be related to emotional distress (anxiety, depression and anger). in addition, behavioral treatment of emotional distress is known to decrease symptoms, and treatment usage. the present protocol tests whether the addition of a medication known to reduce emotional distress can also reduce symptoms and treatment usage. this will done by recruiting patients with acs during their hospital stay, randomizing them to receive citalopram or placebo, and then examining their symptoms and treatment usage at 6 months.

not applicable. study not funded.

Eligibility criteria:
inclusion criteria: * admission to hospital for chest pain/dyspnea, typical ecg changes plus positive tropinins exclusion criteria: * age less than 18 * cognitive impairment (per mmse) * geographic unavailability for followup * unwillingness to participate * illiteracy * hx cardiac transplant * untreated hypothyroidism * hepatic dysfunction * prior adverse reaction to citalopram * history of bipolar disorder * untreated sleep apnea * chronic steroid therapy * active substance abuse (e.g., within past year) * near term mortal illness * current mental health treatment * signitificant suicide risk

Keywords: angina acute coronary syndrome emotional distress citalopram health care utilization
switching from tobramycin inhalation treatment to tobramycin inhaler treatment: the effect on cf patients' adherence and quality of life

Conditions: Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler

Summary: pseudomonas is a common and virulent respiratory bacteria in patients with cystic fibrosis (cf). with time, the infection with pseudomonas becomes chronic and very difficult to eradicate. the standard treatment of chronic pseudomonas infection is inhaled tobramycin which is given every other month.. inhalation of tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. however, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. the effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.


Eligibility criteria:
inclusion criteria: * age 6 years and above, chronic pseudomonas infection exclusion criteria: * younger than 6 years; no chronic pseudomonas infection

Keywords: cystic fibrosis, chronic pseudomonas infection, inhaled tobramycin
prognostic value of cd318 in aml at assiut university hospital.

Conditions: Acute Myeloid Leukemia

Summary: we will focus on the prognostic value of cd318 in acute myeloid leukemia patients at assiut university hospital

acute myeloid leukemia (aml) is a disease with high mortality and variable prognosis . it remains a disease with a highly variable outcome depending on the exact footprint of the aml .although many patients with aml have a response to induction therapy ,refractory disease is common and relapse represents the major cause of treatment failure .in 2016 the world heath organization published revisions to classification of myeloid neoplasms and acute leukemias .well-established prognostic factors are cytogenetic aberrations such as t(8;21), inv(16), and t(15;17) as well as mutated idh1/2, npm1, and flt3 genes but only few markers can specifically predict the outcome after hsct .immunophenotyping via flowcytometry comprises an additional fast technique to predict outcome in aml, although only few markers are yet established as prognostic factors in clinical routine diagnosis, despite the fact that new and rapidly available markers are needed to improve the treatment decisions in aml patients. this is even more since starting therapy in aml patients must be initiated immediately after diagnosis . overall mortality from aml is high and treatment should be initiated within hours after first diagnosis . in hematopoietic cells,cd318 has been identified as stem cell marker for both benign and malignant progenitor cells. cd318+ bone marrow or cord blood-derived cells have been shown to be capable to initiate multi-lineage hematopoiesis in vitro and in vivo .cd318 (cub domain containing protein-1, cdcp1) is a highly glycosylated single pass transmembrane protein express endomesenchymal and neural stem cells and fibroblasts and hematopoietic.overexpression of cd318 has been recently correlated with poor overall survival(os) in colonic ,breast ,renal, hepatocellular ,and pancreatic carcinoma.possibly due to its role in metastasis formation via interaction with integrins and anti-apoptotic signaling via akt. of aml blasts, pronounced cd318 expression has been observed on the immature cd34+cd133+ leukemic cells subset implicated to be enriched for leukemic stem. however, the impact of cd318 on survival in hematological malignancies has so far not been analyzed. study done by jonas s et al showed 57% of aml patients expressed relevant cd318 levels and a significant correlation of cd 318 surface levels with prognosis was observed . in our study investigators will use flowcytometry to detect cd318 on aml blasts and correlate it with disease course and outcome.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed aml patients 2. age more than 18 years 3. patients not starting chemotherapy yet 4. primary aml 5. secondary aml on top of mds or myeloproliverative noeplasms exclusion criteria: 1. refractory aml patients 2. relapsed aml patients
difference of plantar pressure distribution between surgical treatment and conservative treatment for cai

Conditions: Chronic Ankle Instability

Summary: the objective of this study was to compare the difference of plantar pressure distribution between surgical treatment and conservative treatment for cai.

the data of 20 patients who underwent surgery after reconstruction of the lateral collateral ligament of the ankle joint and 20 patients who underwent balance rehabilitation training were analyzed to compare the clinical effects of surgical treatment and conservative treatment for chronic ankle instability, in order to better guide the selection of the optimal intervention program for patients with chronic ankle joint.

Eligibility criteria:
inclusion criteria: * patients diagnosed with cai * the contralateral ankle joint is healthy exclusion criteria: * accompanied by other musculoskeletal injuries
the effect of arginine on biofilm composition, architecture and metabolism

Conditions: Dental Caries; Dental Plaque; Microbial Colonization

Summary: arginine is an adjunct to oral health care that has the potential to modulate the composition and activity of the microbial community of dental biofilms towards a health-related status without harmful effects for the resident oral microbiota. the aim of the study is to investigate the effects of arginine treatment compared to placebo on the composition, metabolism, and microarchitecture of biofilms grown in situ in the oral cavity of caries-active participants.


Eligibility criteria:
inclusion criteria: * males and females ≥ 18 years old. * three or more active carious lesions. * anatomically possible to manufacture an intraoral lower-jaw splint. * able to understand and follow instructions, as well as to read and sign the informed consent form. exclusion criteria: * history of allergies towards any of the ingredients in the test products * self-reported pregnant or nursing * antibiotic or anti-inflammatory medication within 90 days of the screening visit. * orthodontic appliances, including retainers, or removable partial dentures. * self-reported serious medical conditions.
incisions for cardiac surgery

Conditions: Cardiac Surgery; Cardiac Diseases

Summary: the purpose is to evaluate the investigators' length of incisions based on patient weight, operative times, hospital lengths of stay, pain medicine requirements, complications and costs. these data will lead to a new minimally invasive standard of care without a reduction in outcomes.

there is a trend in surgery, in general, toward minimal invasion. this includes the transition to laparoscopy/thoracoscopy from open procedures, as well as the reduction in incision size for open procedures. the goal of minimally invasive techniques is to reduce morbidity and length of hospital stay, with a consequent reduction in hospital cost. there are few cardiac operations that are currently performed with minimally invasive techniques. one of these is the repair of an atrial septal defect, which can be performed though a small skin incision and partial rather than full sternotomy. another is the ligation of a patent ductus arteriosus, which can be performed through a muscle-sparing thoracotomy rather than a full thoracotomy. both of these techniques minimize the scarring and the healing time required for post-operative recovery. we need to be confident that it has not affected our outcomes adversely. we need to evaluate our length of incisions based on patient weight, operative times, hospital lengths of stay, pain medicine requirements, complications and costs. hopefully, these data will lead to a new minimally invasive standard of care without a reduction in outcomes. we will review charts before november 1, 2004 at children's healthcare of atlanta.

Eligibility criteria:
inclusion criteria: * children who have undergone cardiac surgery at children's healthcare of atlanta * surgery before november 1, 2004 exclusion criteria; those who do not fall under the above inclusion criteria

Keywords: pediatric health cardiac small incisions operations minimally invasive
an italian randomized open-label study of occipital nerve stimulation in the treatment of chronic migraine headache

Conditions: Headache, Migraine

Summary: the purpose of this study is to evaluate the safety and the efficacy of occipital nerve stimulation treating chronic migraine headache


Eligibility criteria:
inclusion criteria: * patients with migraine * patients 18 years aged or above exclusion criteria: * patients which participated within the last 30 days or plan to participate during this study in another device or drug trial * patients pregnant or planning on becoming pregnant during the study period

Keywords: headache migraine
effects of pinitol on hidrocarbonated metabolism parameters in diabetic, impaired and normal fasting glucose subjects

Conditions: Type 2 Diabetes; Impaired Glucose Tolerance; Healthy

Summary: the purpose of this study was to assess whether pinitol improves hidrocarbonated metabolism parameters, and evaluate its effect on oxidative stress and endothelial function in diabetic, impaired and normal fasting glucose subjects. this was a 3-month randomised, controlled-placebo, parallel trial with a three-arm design. patients were divided into three groups: diabetic (n=40), impaired fasting glucose (n=40) or normal fasting glucose subjects (n=40), receiving 4 g/day of pinitol/placebo.


Eligibility criteria:
inclusion criteria: * age range of 18-70 years. * normal fasting glucose subjects were diagnosed as fasting glucose \<100 mg/dl and hba1c \<5.7%. * impaired fasting glucose subjects were diagnosed as fasting glucose between 100 and 125 mg/dl and/or hba1c between 5.7 and 6.4%. * type 2 diabetes subjects were diagnosed as basal plasma glucose ≥ 126 mg/dl, at least twice, or glucose levels 2 hours after 75 g oral glucose overload ≥ 200 mg/dl (american diabetes association) exclusion criteria: * morbid obesity * type 1 diabetes * heart, liver, thyroid or kidney untreated disease * neoplasic disease * hypertriglyceridemia (triglycerides \>400 mg/dl), * use of drugs that can influence the inflammatory state or insulin sensitivity (nsaids, corticosteroids, antitnfα) and * uncontrolled type 2 diabetes (hba1c ≥ 8%) or with insulin or intestinal disaccharidase inhibitors (acarbose, miglyol,...) treatment.
piezo-surgical implant with laser

Conditions: Effect of Piezo-surgical Implant With Laser on Pain and Swelling in Patients With Missing Teeth

Summary: evaluation of the effect of laser with piezo-surgical device in dental implants


Eligibility criteria:
inclusion criteria: * healthy subjects having good oral hygiene * history of bilateral extractions in the lower molar area not less than 6 months ago. exclusion criteria: * patients with debilitating diseases or bad oral hygiene, * patients with parafunctional habits and patients who are taking analgesics or with alcohol abuse.
additional neurological symptoms before surgery of the carotid arteries - a prospective study (ansyscap)

Conditions: Carotid Stenoses

Summary: a single center observational study. observing the time between cerebrovascular symptoms and carotid endarterectomy (cea) and patient outcome. an intervention at 17 of the 29 study months aimed at reducing the delay and increasing the patient safety. main outcome is to measure the reduction in recurrent stroke with decreased delay to cea.

all patients with a carotid stenosis \>50% according to the nascet-criteria are included. the study does not affect the health care the patients receive. the time between symptom and surgery is compared to the outcome of the cea after 45 days, 6 months, 1 year and 5 years. an intervention in the form of new practical local and regional guidelines in january 2009 (#17 of the 29 study months) aimed at reducing the delay and increasing the patient safety. primary aim: to study the risk of ipsilateral stroke, any stroke, death, any cerebrovascular event, any cardiovascular event. two primary analyses: 1. ipsilateral ischemic stroke within 90 days of the presenting event. this analysis is aimed at the short term risk of pre-operative stroke. survival analysis will be used. cea will be used a censor, thus excluding all peri-operative and postoperative strokes. 2. all primary endpoints within 5 years of the presenting event. this analysis is aimed att the long term risk of cardio-vascular morbidity and mortality. secondary analyses: 1) same as first primary analysis, but including all stroke as endpoint, not only ipsilateral ischemic stroke. secondary aim: to attempt to validate different risk and score systems already published by other sources. such as can abcd2-score be used safely to chose between acute and fast normal screening for carotid stenosis?

Eligibility criteria:
inclusion criteria: * carotid stenosis \>50% according to nascet criteria exclusion criteria: * not preliminary judged as having an indication for surgery, before an extensive investigation is launched. thus, some patients that will not undergo cea will be included.

Keywords: carotid stenosis carotid endarterectomy
lesion load and location in relation to cognition, fatigue and physical disability in rrms

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: in relapsing remitting multiple sclerosis (rrms) the relationship between cognitive impairment (ci), fatigue and physical disability with white matter lesion load (wm-ll), location among other volumetric measures using automated platforms is still unclear.

cognitive impairment (ci) and fatigue have been recognized as an important feature of ms, affecting up to 70% patients (1), evident since onset and increase in both prevalence and severity as the disease progresses (2). in fact, their effects on patients and even their caregivers are more pronounced than clinical disability, causing unemployment, treatment non-adherence, personality changes as well as several psychosocial dysfunctions (3-5). therefore, beside evaluating the physical disability, it is essential for health professionals to objectively evaluate either the cognitive function or fatigue at both baseline and during routine follow up visits for early detection and management (6). through the advances in mri techniques and availability of a number of automated software, quantitative radiological assessments became more readily available and feasible in daily practice (7) allowing objective longitudinal monitoring of patients (8,9). although burden and location of lesions in rrms is thought to be associated with cognitive impairment (ci), fatigue and physical disability, some controversy results were obtained from previous studies. so, by conducting this study, we aimed at exploring the relationship between different parameters of lesion load and location with fatigue, cognitive and physical disability in rrms patients.

Eligibility criteria:
inclusion criteria: * : adult patients of both sexes diagnosed with rrms according to 2017 mcdonald diagnostic criteria exclusion criteria: * patients with relapse or steroid administration in the past 30 days were excluded. patients who have any medical conditions that may affect cognition, and those on psychoactive pharmacotherapy were also excluded.
dorsomedial prefrontal cortex and the antidepressant efficacy of theta burst stimulation in depressed patients

Conditions: Treatment Resistant Depression

Summary: this study evaluates an association between different dosage and the antidepressant efficacy of theta burst stimulation in patients with treatment-resistant depression. in a double-blind design, all patients are randomized to three groups, i.e. standardized dosage intermittent theta-burst stimulation treatment, high dosage intermittent theta-burst stimulation treatment or sham treatment.


Eligibility criteria:
inclusion criteria: * male or female, 21 to 70 years of age. * diagnosed with the recurrent major depressive disorder (mdd) and currently having a major depressive episode (mde) * participants failed to respond to at least one adequate antidepressant treatment in their current episode * participants have a clinical global impression - severity score of at least 4 and a total score of at least 18 on the hamilton depression rating scale (hdrs-17) at both screening and baseline visits ( day -14 and day 0) * participants must discontinue their antidepressant medications at least for one week ( at least two weeks if fluoxetine) prior to the tms intervention and keep antidepressant-free during the study duration. * participants also failed to respond to one complete left-sided dlpfc 10hz rtms/pitbs treatment course. exclusion criteria: * a lifetime psychiatric history of bipolar disorder, schizophrenia, psychotic disorders, or organic mental disorder including substance abuse and dependence (based on dsm-iv criteria) * participants with a lifetime medical history of major systemic illness and clinically significantly abnormal screening examination that might affect safety, study participation, or confound interpretation of study results. * participants with a lifetime medical history of neurological disorder records (e.g., stroke, seizure, traumatic brain injury, post brain surgery), brain implants (neurostimulators), cardiac pacemakers * women with breastfeeding or pregnancy * participants with a current strong suicidal risk (i.e., a score of 4 on item 3 of the hdrs-17)